Preclinical comparison reveals CAR T cells achieve superior tumor control and antitumor activity in AML, indicating potential benefits of co-stimulatory signals.
Key Points
CAR T cells achieved superior tumor control in AML models, enhancing survival compared to BiTE molecules.
In vitro experiments demonstrated CD86-mediated co-stimulation improves antitumor activity of BiTE-redirected T cells.
Transcriptional profiling indicated unique exhaustion signatures in T cells from FLT3 BiTE-treated mice.
Insights suggest strategies to enhance T-cell-based therapies against myeloid malignancies.